Last updated on May 2019

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Brief description of study

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.

Clinical Study Identifier: NCT03814291

Find a site near you

Start Over